20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is ALBENDAZOLE (B) USP, with a corresponding US DMF Number 30967.
Remarkably, this DMF maintains an Active status since its submission on October 28, 2016, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 13, 2017, and payment made on September 29, 2016, indicating their dedication to facilitating drug approvals, Categorized as Type II